

Clinical Trial Protocol

Iranian Registry of Clinical Trials

19 Aug 2022

Double-blind placebo-controlled clinical trial of evaluating the effectiveness of Ivermectin in treatment of patients admitted with COVID-19 in 2021

Protocol summary

Study aim

Determining the effect of ivermectin on RT-PCR test, clinical improvement, mortality and duration of hospitalization in patients admitted with COVID-19

Design

Clinical trial with control group, parallel groups, double-blind, randomized, phase 3 on 1000 patients. Patients will be divided into two groups by a simple randomization method with a table of random numbers. The control group will receive standard and placebo treatment and the intervention group will receive Ivermectin for three days in addition to the standard treatment.

Settings and conduct

COVID-19 positive rapid test or RT-PCR patients admitted to Buali and Imam hospitals of Sari, Razi hospital of Qaemshahr, Imam Hossein hospital of Neka and Imam hospital of Fereidoonkenar will be divided into two groups of intervention and control. The present study will be double-blind so that patients and physicians will be unaware of how the intervention and control groups assigned.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients with COVID-19 positive rapid test or RT-PCR; aged >5 years; weight more than 15 kg and without liver and lung disease and acquired immunodeficiency and pregnancy lactation and without treatment with antiviral drugs before and during the study are included.

Intervention groups

Intervention group: Iranian standard treatment protocol for COVID-19 in addition to 6mg Ivermectin tablet made by Alborz Daru Company of Iran for 3 days. Control group: In the control group, placebo tablets made by Alborz Daru Company of Iran with the same shape, color and weight based dose of ivermectin will be used for three days.

Main outcome variables

Clinical improvement, Duration of hospital stay, Rate of Mortality

General information

Reason for update

Increase in sample size and pharmaceutical company

Acronym

IRCT registration information

IRCT registration number: **IRCT20111224008507N5**

Registration date: **2021-02-22, 1399/12/04**

Registration timing: **registered_while_recruiting**

Last update: **2021-03-04, 1399/12/14**

Update count: **1**

Registration date

2021-02-22, 1399/12/04

Registrant information

Name

Mohammadsadegh Rezai

Name of organization / entity

Mazandaran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 15 1325 7230

Email address

rezai@mazums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-02-19, 1399/12/01

Expected recruitment end date

2021-08-22, 1400/05/31

Actual recruitment start date

empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Double-blind placebo-controlled clinical trial of evaluating the effectiveness of Ivermectin in treatment of patients admitted with COVID-19 in 2021

Public title
Evaluation of the effect of Ivermectin in treatment of patients admitted with COVID-19

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Patients with positive coronavirus rapid test or RT-PCR
Age>5 years Weight >15 kg No treatment with antiviral drugs before and during the study Informed consent for participation
Exclusion criteria:
Underlying liver and kidney disease Patients with acquired immunodeficiency Pregnancy and lactation

Age
From **5 years** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Investigator

Sample size
Target sample size: **1000**

Randomization (investigator's opinion)
Randomized

Randomization description
First, using the Random number generation plugin in excel software, a table of random numbers from 1 to 1000 is prepared in a non-sequential and scattered manner, and the numbers are assigned to two intervention and control groups of 500 cases. The randomization process is performed by the methodology consultant and clinical researchers are not aware of the randomization process and will only be provided with random codes from 1 to 1000.

Blinding (investigator's opinion)
Double blinded

Blinding description
After selecting the samples, none of the participants will be aware of randomization and allocation to groups. Physicians will be given a table of pre-coded numbered numbers and patients will be entered into the study in order of table numbers. Therefore, the present study will be double-blind. Ivermectin and placebo tablets will be in the same shape, color and size and will be delivered to the patient/parents in a package.

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Mazandaran University of Medical Sciences

Street address

Vice chancellor for Research, Moallem square, Sari

City

Sari

Province

Mazandaran

Postal code

4712855689

Approval date

2021-01-27, 1399/11/08

Ethics committee reference number

IR.MAZUMS.REC.1399.915

Health conditions studied

1

Description of health condition studied

COVID-19 infection

ICD-10 code

U07.1

ICD-10 code description

COVID-19, virus identified

Primary outcomes

1

Description

Reduction in persistent cough

Timepoint

Daily until improvement

Method of measurement

Question from the patient

2

Description

Negative RT-PCR result

Timepoint

6 days after the intervention

Method of measurement

RT-PCR

3

Description

The main complaints recovery time

Timepoint

Daily until symptoms resolve

Method of measurement

Checklist containing patient complaints

4

Description

Mortality

Timepoint

Daily

Method of measurement

Record in checklist

5

Description

Drug side effect (Wheezing, itching, skin rash, edema, and hypotension)

Timepoint

Daily

Method of measurement

Question from the patient

6

Description

Reduction in tachypnea

Timepoint

Daily

Method of measurement

Medical record

7

Description

Oxygen saturation >94%

Timepoint

Daily

Method of measurement

Medical record

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: The intervention group will use Iranian standard treatment protocol for COVID-19 in addition to Ivermectin 3 mg oral tablet at a dose of 0.4 mg/kg manufactured by Alborz Daru of Iran for 3 days as follows: weight 15-24, 6 mg; Weight 35-25, 12 mg; Weight 50-36, 18 mg; Weight 80-5, 24 mg and weight over 80, 0.4 mg/kg

Category

Treatment - Drugs

2

Description

Control group: In the control group, placebo tablets made by Alborz Daru of Iran with the same shape, color and weight based dose of ivermectin will be used for three days.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Imam and Buali hospitals of Sari, Razi hospital of Qaemshahr, Imam Hossein hospital of Neka and Ima

Full name of responsible person

Dr Mohammad Sadegh Rezai

Street address

Bouali Hospital, Pasdaran boulevard, Sari

City

Sari

Province

Mazandaran

Postal code

4815838477

Phone

+98 11 3334 2334

Email

drmsrezai@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Mazandaran University of Medical Sciences

Full name of responsible person

Dr. Majid Saeidi

Street address

Vice chancellor for Research, Moallem square, Sari

City

Sari

Province

Mazandaran

Postal code

4712855689

Phone

+98 11 3334 2334

Email

msaeidi@mazums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Mazandaran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Dr Mohammad Sadegh Rezai
Position
Professor
Latest degree
Subspecialist
Other areas of specialty/work
Pediatrics
Street address
Boali Hospital, Pasdaran Blv., Sari
City
Sari
Province
Mazandaran
Postal code
4815838477
Phone
+98 11 3334 2334
Fax
+98 11 3334 2334
Email
drmsrezai@yahoo.com
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Dr Mohammad Sadegh Rezai
Position
Professor
Latest degree
Subspecialist
Other areas of specialty/work
Pediatrics
Street address
Bouali Hospital, Pasdaran Boulevard, Sari
City
Sari
Province
Mazandaran

Postal code
4815838477
Phone
+98 11 3334 2334
Email
drmsrezai@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity
Mazandaran University of Medical Sciences
Full name of responsible person
Fatemeh Hosseinzadeh
Position
Research Expert
Latest degree
Master
Other areas of specialty/work
Midwifery
Street address
Bouali Hospital, Pasdaran Boulevard, Sari
City
Sari
Province
Mazandaran
Postal code
4815838477
Phone
+98 11 3334 2334
Email
fatima.hzade@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Not applicable

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Not applicable

Data Dictionary

Not applicable

Title and more details about the data/document

Part of the data is accessible

When the data will become available and for how long

Starting in January 2022

To whom data/document is available

Physicians

Under which criteria data/document could be used

Systematic review articles

From where data/document is obtainable

Contact Dr. Mohammad Sadegh Rezai. E-mail:
drmsrezai@yahoo.com

What processes are involved for a request to access

data/document

After contact, information is sent within a few days
Comments